Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027066 (
myoclonus
)
4,275
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Norepinephrine
, epinephrine, dopamine, serotonin and their major catabolites were measured in 17 regions of the left hemisphere of two brains obtained from two brothers with Alzheimer's disease with very early onset. The clinical diagnosis was confirmed by histological examination of the right hemispheres and brain stems. The quantitative data were compared with our values in normal brains. In the patient suffering from the less severe dementia, there was a severe reduction of the serotonin concentration in all examined neocortical areas and its concentration was even below the detection limit in the nucleus amygdalis, hippocampus, caudate nucleus, putamen, globus pallidus and substantia nigra. In the other patient, who suffered from a more pronounced dementia with
myoclonus
, the serotonin concentration was below the detection limit in all examined structures. In contrast with these findings, the noradrenergic, adrenergic and dopaminergic systems appeared to be relatively unaffected by the disease process. Focusing our attention on the nuclei wherein the monoamine transmitter systems originate, it appeared that neuronal losses and neurofibrillary tangles clearly predominated in the substantia grisea subependymalis, the nucleus centralis superior and the nucleus raphe dorsalis, origin of the main serotonergic system. The serotonin deficiency sheds light on possible mechanisms of
myoclonus
in Alzheimer's disease.
...
PMID:Distribution of biogenic amines and their catabolites in brains from patients with Alzheimer's disease. 381 69
1 The effect of catechol on uptake and K+-stimulated release of gamma-aminobutyric acid (GABA), D-aspartate, noradrenaline and acetylcholine has been studied in slices of cerebral cortex and thalamus. 2 Low concentrations of catechol did not influence the uptake of any of the neurotransmitters in either brain area. 3
Noradrenaline
release was unaffected by catechol. 4 Acetylcholine release from both cortical and thalamic slices was inhibited by high concentrations of catechol. This phenomenon is unlikely to be related to catechol-induced convulsions. 5 Catechol (100 microM) inhibited GABA release from cortical slices by 28%. However, at a concentration of 10 microM catechol enhanced the release of D-aspartate from thalamic slices by over 100%. 6 Potentiated release of excitatory amino acid transmitters may contribute to the enhanced excitability of thalamic cells which occurs during sensory
myoclonus
induced by low doses of catechol.
...
PMID:The effect of the convulsant agent, catechol, on neurotransmitter uptake and release in rat brain slices. 611 45